Sonia S Lin1, Sean T Massa1, Mark A Varvares2. 1. Department of Internal Medicine, University of Southern California Keck School of Medicine, Los Angeles, California. 2. Department of Otolaryngology, Head and Neck Surgery, Saint Louis University School of Medicine, Saint Louis University Cancer Center, Saint Louis, Missouri.
Abstract
BACKGROUND: Many studies have demonstrated the advantage of postoperative concurrent chemoradiotherapy (CRT) over radiotherapy (RT) alone in locoregional control, but few have examined overall survival with respect to national databases. METHODS: The literature was searched for eligible randomized controlled trials. The Surveillance, Epidemiology, and End Results (SEER) Database and National Cancer Data Base (NCDB) were searched for 5-year overall survival data. RESULTS: Twenty-eight studies were examined and demonstrated 44% greater locoregional control (relative risk [RR] = 0.56; 95% confidence interval [CI] = 0.46-0.68) and 12% overall survival benefit (RR = 0.88; 95% CI = 0.81-0.98) with postoperative adjuvant CRT compared to adjuvant RT. Overall SEER survival was 45.0% in 1973, rising to 53.2% in 2005. The NCDB documents a similar increase in overall survival from 45.5% in 1994 to 53.4% in 2005. CONCLUSION: The literature shows mortality benefit of adjuvant CRT in patients with advanced head and neck cancer, reflected in SEER and NCDB.
BACKGROUND: Many studies have demonstrated the advantage of postoperative concurrent chemoradiotherapy (CRT) over radiotherapy (RT) alone in locoregional control, but few have examined overall survival with respect to national databases. METHODS: The literature was searched for eligible randomized controlled trials. The Surveillance, Epidemiology, and End Results (SEER) Database and National Cancer Data Base (NCDB) were searched for 5-year overall survival data. RESULTS: Twenty-eight studies were examined and demonstrated 44% greater locoregional control (relative risk [RR] = 0.56; 95% confidence interval [CI] = 0.46-0.68) and 12% overall survival benefit (RR = 0.88; 95% CI = 0.81-0.98) with postoperative adjuvant CRT compared to adjuvant RT. Overall SEER survival was 45.0% in 1973, rising to 53.2% in 2005. The NCDB documents a similar increase in overall survival from 45.5% in 1994 to 53.4% in 2005. CONCLUSION: The literature shows mortality benefit of adjuvant CRT in patients with advanced head and neck cancer, reflected in SEER and NCDB.
Authors: Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-04-01 Impact factor: 6.223
Authors: Eric Adjei Boakye; Paula Buchanan; Leslie Hinyard; Nosayaba Osazuwa-Peters; Mario Schootman; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-08-01 Impact factor: 6.223
Authors: Nosayaba Osazuwa-Peters; Sean T Massa; Kara M Christopher; Ronald J Walker; Mark A Varvares Journal: J Cancer Res Clin Oncol Date: 2015-10-28 Impact factor: 4.553
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-03-01 Impact factor: 6.223
Authors: Jason Tasoulas; Nicholas R Lenze; Douglas Farquhar; Travis P Schrank; Colette Shen; M Ali Shazib; Bart Singer; Shetal Patel; Juneko E Grilley Olson; David N Hayes; Margaret L Gulley; Bhishamjit S Chera; Trevor Hackman; Andrew F Olshan; Jared Weiss; Siddharth Sheth Journal: Cancer Med Date: 2021-05-02 Impact factor: 4.452
Authors: Shannon F Rudy; J Chad Brenner; Jennifer L Harris; Jun Liu; Jianwei Che; Megan V Scott; John Henry Owen; Christine M Komarck; Martin P Graham; Emily L Bellile; Carol R Bradford; Mark E P Prince; Thomas E Carey Journal: J Otolaryngol Head Neck Surg Date: 2016-04-26